Allucent to expedite Covid-19 booster vaccines development
Pharmaceutical Business Review
AUGUST 28, 2023
These candidates are being developed to offer better protection, extend the duration in preventing illness and transmission, as compared to the current vaccine technologies. As part of the contract, Allucent will initiate a Phase IIb clinical trial of 10,000 participants under BARDA’s Clinical Studies Network.
Let's personalize your content